Simple and cost-effective UV spectrophotometric platforms integrating advanced green and blue metrics for concurrent analysis of dapagliflozin and vildagliptin in diabetes therapy.

Eman Darweish, Hisham A Hashem, Rawan Nasr, Eman A Bahgat

Abstract read

In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Eman DarweishPharmaceutical Chemistry Department, Faculty of Pharmacy, Egyptian Russian University, Badr City, 11829, Cairo, Egypt.

Hisham A HashemAnalytical Chemistry Department, Faculty of Pharmacy, Zagazig University, Zagazig, 44519, Egypt.

Rawan NasrPharmaceutical Chemistry Department, Faculty of Pharmacy, Egyptian Russian University, Badr City, 11829, Cairo, Egypt. rawan-nasr@eru.edu.eg.

Eman A BahgatAnalytical Chemistry Department, Faculty of Pharmacy, Zagazig University, Zagazig, 44519, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The co-administration of dapagliflozin (DPF) and vildagliptin (VLT) in tablet dosage forms is a clinically established strategy for managing of type 2 diabetes mellitus and has demonstrated favorable therapeutic outcomes. Nevertheless, the simultaneous quantitative determination of both drugs remains challenging because of the severe overlap in their UV absorption spectra, with λ

Indexed as

Benzhydryl CompoundsDiabetes Mellitus, Type 2GlucosidesHypoglycemic AgentsVildagliptinHumansLimit of DetectionSpectrophotometry, UltravioletTabletsBenzhydryl CompoundsdapagliflozinGlucosidesHypoglycemic AgentsTabletsVildagliptinClick Analytical Chemistry Index (CACI)Dapagliflozin (DPF)Deconvoluted Fourier (DF)Vildagliptin (VLT)

Identifiers

PMID42350572

DOI10.1038/s41598-026-58523-w

PMCPMC13303919

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.